• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

运用代谢组学阐明癸氧喹酯衍生物RMB041的抗分枝杆菌作用机制

Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics.

作者信息

Knoll Kirsten E, Lindeque Zander, Adeniji Adetomiwa A, Oosthuizen Carel B, Lall Namrita, Loots Du Toit

机构信息

Human Metabolomics, North-West University, Private Bag x6001, Box 269, Potchefstroom 2531, South Africa.

Department of Plant and Soil Sciences, Faculty of Natural and Agricultural Sciences, University of Pretoria, Pretoria 0002, South Africa.

出版信息

Antibiotics (Basel). 2021 Jun 10;10(6):693. doi: 10.3390/antibiotics10060693.

DOI:10.3390/antibiotics10060693
PMID:34200519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8228794/
Abstract

Tuberculosis (TB), caused by (), still remains one of the leading causes of death from a single infectious agent worldwide. The high prevalence of this disease is mostly ascribed to the rapid development of drug resistance to the current anti-TB drugs, exacerbated by lack of patient adherence due to drug toxicity. The aforementioned highlights the urgent need for new anti-TB compounds with different antimycobacterial mechanisms of action to those currently being used. An -alkyl quinolone; decoquinate derivative RMB041, has recently shown promising antimicrobial activity against , while also exhibiting low cytotoxicity and excellent pharmacokinetic characteristics. Its exact mechanism of action, however, is still unknown. Considering this, we used GCxGC-TOFMS and well described metabolomic approaches to analyze and compare the metabolic alterations of treated with decoquinate derivative RMB041 by comparison to non-treated controls. The most significantly altered pathways in treated with this drug include fatty acid metabolism, amino acid metabolism, glycerol metabolism, and the urea cycle. These changes support previous findings suggesting this drug acts primarily on the cell wall and secondarily on the DNA metabolism of . Additionally, we identified metabolic changes suggesting inhibition of protein synthesis and a state of dormancy.

摘要

由()引起的结核病(TB)仍然是全球单一感染源导致死亡的主要原因之一。这种疾病的高流行率主要归因于对当前抗结核药物耐药性的迅速发展,而药物毒性导致患者依从性差又加剧了这一情况。上述情况凸显了迫切需要研发具有与目前所用药物不同抗分枝杆菌作用机制的新型抗结核化合物。一种 - 烷基喹诺酮;癸氧喹酯衍生物RMB041,最近显示出对()有良好的抗菌活性,同时还表现出低细胞毒性和优异的药代动力学特性。然而,其确切的作用机制仍然未知。考虑到这一点,我们使用气相色谱 - 飞行时间质谱联用(GCxGC - TOFMS)以及成熟的代谢组学方法,通过与未处理的()对照进行比较,分析和比较用癸氧喹酯衍生物RMB041处理后的()的代谢变化。用这种药物处理后的()中变化最显著的途径包括脂肪酸代谢、氨基酸代谢、甘油代谢和尿素循环。这些变化支持了先前的研究结果,表明这种药物主要作用于()的细胞壁,其次作用于其DNA代谢。此外,我们还确定了表明蛋白质合成受到抑制和处于休眠状态的代谢变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/331a/8228794/777803fd7668/antibiotics-10-00693-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/331a/8228794/8c4bf302d362/antibiotics-10-00693-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/331a/8228794/d2ae6c3ea8fa/antibiotics-10-00693-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/331a/8228794/777803fd7668/antibiotics-10-00693-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/331a/8228794/8c4bf302d362/antibiotics-10-00693-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/331a/8228794/d2ae6c3ea8fa/antibiotics-10-00693-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/331a/8228794/777803fd7668/antibiotics-10-00693-g003.jpg

相似文献

1
Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics.运用代谢组学阐明癸氧喹酯衍生物RMB041的抗分枝杆菌作用机制
Antibiotics (Basel). 2021 Jun 10;10(6):693. doi: 10.3390/antibiotics10060693.
2
Drug Discovery Strategies Identified ADMET Properties of Decoquinate RMB041 and Its Potential Drug Targets against Mycobacterium tuberculosis.药物发现策略鉴定了癸氧喹酯 RMB041 的 ADMET 性质及其针对结核分枝杆菌的潜在药物靶点。
Microbiol Spectr. 2022 Apr 27;10(2):e0231521. doi: 10.1128/spectrum.02315-21. Epub 2022 Mar 30.
3
An ADME and Pharmacokinetic Study of Novel TB-Active Decoquinate Derivatives.新型抗结核药地考喹酯衍生物的吸收、分布、代谢和排泄及药代动力学研究
Front Pharmacol. 2019 Feb 18;10:120. doi: 10.3389/fphar.2019.00120. eCollection 2019.
4
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.社论:结核杆菌药物靶点的现状与展望以及基于构效关系的抗结核药物设计
Curr Pharm Des. 2014;20(27):4305-6. doi: 10.2174/1381612819666131118203915.
5
Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.利用代谢组学阐明环丙沙星的抗分枝杆菌作用机制
Microorganisms. 2021 May 28;9(6):1158. doi: 10.3390/microorganisms9061158.
6
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
7
Elucidating the antimicrobial mechanisms of colistin sulfate on Mycobacterium tuberculosis using metabolomics.运用代谢组学阐明硫酸黏菌素对结核分枝杆菌的抗菌机制。
Tuberculosis (Edinb). 2018 Jul;111:14-19. doi: 10.1016/j.tube.2018.05.001. Epub 2018 May 8.
8
Metabolomics of colistin methanesulfonate treated Mycobacterium tuberculosis.多粘菌素甲磺酸盐处理的结核分枝杆菌的代谢组学
Tuberculosis (Edinb). 2018 Jul;111:154-160. doi: 10.1016/j.tube.2018.06.008. Epub 2018 Jun 13.
9
Metabolic Rewiring of upon Drug Treatment and Antibiotics Resistance.药物治疗与抗生素耐药性下的代谢重编程
Metabolites. 2024 Jan 18;14(1):63. doi: 10.3390/metabo14010063.
10
Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in .中心碳代谢重编程作为产生药物耐受性和耐药性的机制。
Front Cell Infect Microbiol. 2022 Aug 22;12:958240. doi: 10.3389/fcimb.2022.958240. eCollection 2022.

引用本文的文献

1
Advancements in Synthetic Strategies and Biological Effects of Ciprofloxacin Derivatives: A Review.环丙沙星衍生物的合成策略及生物效应的研究进展:综述
Int J Mol Sci. 2024 Apr 30;25(9):4919. doi: 10.3390/ijms25094919.
2
Comprehensive Two-Dimensional Gas Chromatography as a Bioanalytical Platform for Drug Discovery and Analysis.全二维气相色谱作为药物发现与分析的生物分析平台
Pharmaceutics. 2023 Mar 31;15(4):1121. doi: 10.3390/pharmaceutics15041121.
3
Metabolomics meets systems immunology.代谢组学与系统免疫学相遇。

本文引用的文献

1
Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.利用代谢组学阐明环丙沙星的抗分枝杆菌作用机制
Microorganisms. 2021 May 28;9(6):1158. doi: 10.3390/microorganisms9061158.
2
Targeting amino acid metabolism of Mycobacterium tuberculosis for developing inhibitors to curtail its survival.针对结核分枝杆菌的氨基酸代谢开发抑制剂以遏制其存活。
IUBMB Life. 2021 Apr;73(4):643-658. doi: 10.1002/iub.2455. Epub 2021 Mar 5.
3
Moxifloxacin Activates the SOS Response in in a Dose- and Time-Dependent Manner.
EMBO Rep. 2023 Apr 5;24(4):e55747. doi: 10.15252/embr.202255747. Epub 2023 Mar 14.
4
The metabolomics of a protein kinase C delta (PKCδ) knock-out mouse model.蛋白激酶 C 德尔塔(PKCδ)敲除小鼠模型的代谢组学。
Metabolomics. 2022 Nov 13;18(11):92. doi: 10.1007/s11306-022-01949-w.
5
Chemical and Pharmacological Properties of Decoquinate: A Review of Its Pharmaceutical Potential and Future Perspectives.癸氧喹酯的化学和药理学特性:对其药用潜力及未来展望的综述
Pharmaceutics. 2022 Jun 30;14(7):1383. doi: 10.3390/pharmaceutics14071383.
6
Drug Discovery Strategies Identified ADMET Properties of Decoquinate RMB041 and Its Potential Drug Targets against Mycobacterium tuberculosis.药物发现策略鉴定了癸氧喹酯 RMB041 的 ADMET 性质及其针对结核分枝杆菌的潜在药物靶点。
Microbiol Spectr. 2022 Apr 27;10(2):e0231521. doi: 10.1128/spectrum.02315-21. Epub 2022 Mar 30.
7
Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches.利用基于系统的组学方法解析结核分枝杆菌宿主-病原体相互作用。
Front Immunol. 2021 Nov 2;12:762315. doi: 10.3389/fimmu.2021.762315. eCollection 2021.
莫西沙星以剂量和时间依赖性方式激活SOS反应。
Microorganisms. 2021 Jan 27;9(2):255. doi: 10.3390/microorganisms9020255.
4
Bacterial Cell Wall Quality Control during Environmental Stress.环境胁迫下的细菌细胞壁质量控制。
mBio. 2020 Oct 13;11(5):e02456-20. doi: 10.1128/mBio.02456-20.
5
Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020.2020 年 1 月至 4 月,冠状病毒病大流行对结核病服务的全球影响。
Emerg Infect Dis. 2020 Nov;26(11):2709-2712. doi: 10.3201/eid2611.203163. Epub 2020 Sep 11.
6
The potential impact of COVID-19-related disruption on tuberculosis burden.新冠疫情相关干扰对结核病负担的潜在影响。
Eur Respir J. 2020 Aug 13;56(2). doi: 10.1183/13993003.01718-2020. Print 2020 Aug.
7
Accumulation of TB-Active Compounds in Murine Organs Relevant to Infection by .结核活性化合物在与感染相关的小鼠器官中的积累 。(原文结尾不完整,翻译可能不太准确)
Front Pharmacol. 2020 May 19;11:724. doi: 10.3389/fphar.2020.00724. eCollection 2020.
8
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials.在结核病治疗临床试验中,坚持治疗的重要性及其在解释性和实用性试验中的相关性。
PLoS Med. 2019 Dec 10;16(12):e1002884. doi: 10.1371/journal.pmed.1002884. eCollection 2019 Dec.
9
WHO global progress report on tuberculosis elimination.世界卫生组织结核病消除全球进展报告。
Lancet Respir Med. 2020 Jan;8(1):19. doi: 10.1016/S2213-2600(19)30418-7. Epub 2019 Nov 6.
10
Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection.破坏结核分枝杆菌天冬氨酸途径以根除持续性感染。
Nat Commun. 2019 Sep 16;10(1):4215. doi: 10.1038/s41467-019-12224-3.